Retatruetide 20mg

Retatrutide is an experimental, next-generation weight-loss and type 2 diabetes medication developed by Eli Lilly and Company. Dubbed a "triple agonist" or "triple G" molecule, it is the first metabolic drug in clinical development to target three different hunger and metabolic hormone receptors simultaneously: GLP-1, GIP, and glucagon. In late-stage Phase 3 clinical trials, retatrutide has demonstrated unprecedented weight loss efficacy, with participants losing an average of 28.3% of their total body weight over 80 weeks on the highest dose.

While existing medications like Ozempic (semaglutide) target only one hormone receptor (GLP-1), and Zepbound (tirzepatide) targets two (GLP-1 and GIP), retatrutide targets three. It works by mimicking:GLP-1 (Glucagon-Like Peptide-1): Suppresses appetite, increases feelings of fullness, and slows stomach emptying.GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin production in response to blood sugar and optimizes how the body breaks down fat.Glucagon (GCG): Directly signals the liver to increase energy expenditure, meaning it actively forces the body to burn more calories and fat throughout the day.